drugset / Trial / NCT03602976
Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis
Phase 2
Terminated
7 enrolled
Ethan Weinberg
American Association for the Study of Liver Diseases · collabMeridian Bioscience, Inc. · collab
Non-randomizedCrossoverOpen-labelTreatment
Summary
This study aims to (1) evaluate efficacy of UDCA in improving liver function and quality of life; (2) monitor safety, tolerability of UDCA, as well as progression of hepatic sarcoidosis and liver disease, in patients diagnosed with hepatic sarcoidosis. A minimum of 10 subjects will be followed for 12 months. For all subjects, initial 6 months will be observational; in subsequent 6 months, UDCA will be administered. Visits will occur every 3 months and involve routine blood collection.
Timeline
- Start
- 2018-08-20
- Primary completion
- 2022-01-12
- Completion
- 2022-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ursodeoxycholic Acid | Small molecule | — | — |
Indications
No indication recorded.